Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
It may be possible to predict the infliximab trough level of both IV and SC infliximab in patients with inflammatory bowel disease during maintenance treatment by using our model in real-world practice.
Authors
- Joo Hye Song (ORCID: https://orcid.org/0000-0002-1166-0085)
- Sung Noh Hong (ORCID: https://orcid.org/0000-0002-4140-3717)
- Dong Kyung Chang (ORCID: https://orcid.org/0000-0001-8925-4629)
- Seong Kyung Kim (ORCID: https://orcid.org/0009-0003-5900-2799)
- Myeong Gyu Kim (ORCID: https://orcid.org/0000-0002-5593-7672)
- Eun Ran Kim (ORCID: https://orcid.org/0000-0002-0495-2565)
- Young‐Ho Kim (ORCID: https://orcid.org/0000-0003-1803-2513)
- Min-Jung Kim (ORCID: https://orcid.org/0000-0001-6304-7664)
Institutions
- Ewha Womans University (KR)
- Samsung Medical Center (KR)
- Konkuk University Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Gut and Liver
- Published
- 2025-04-21
- DOI
- https://doi.org/10.5009/gnl240503
- Citations
- 4
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 7.27
Funders
- Korean Society of Gastroenterology